Literature DB >> 2967644

Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients.

S Weber1, B W Brandom, D M Powers, J B Sarner, S K Woelfel, D R Cook, V J Foster, B F McNulty, J N Weakly.   

Abstract

The neuromuscular and cardiovascular effects of mivacurium were studied in 90 adult patients during nitrous oxide-oxygen-isoflurane (n = 45, ISO group) and nitrous oxide-oxygen-narcotic (n = 45, BAL group) anesthesia. Neuromuscular blockade was measured using electromyographic activity of the adductor pollicis muscle after supramaximal stimulation of the ulnar nerve at 2 Hz for 2 seconds at 10-second intervals. To estimate dose-response relations, three subgroups of nine patients in the ISO group received mivacurium doses of 0.025, 0.03, and 0.04 mg/kg, respectively. Similarly, three subgroups of nine patients in the BAL group received mivacurium doses of 0.03, 0.04, and 0.05 mg/kg, respectively. The ED50 and ED95 of mivacurium in each group were estimated from linear regression plots of log dose vs probit of maximum percentage depression of neuromuscular function. The estimated ED50 values for the ISO and BAL groups were 0.029 and 0.041 mg/kg, respectively. The estimated ED95 values for the ISO and BAL groups were 0.045 and 0.058 mg/kg, respectively. Recovery indexes were measured in 26 patients who received ED95 or greater doses of mivacurium in either the ISO or BAL groups. The recovery index was shorter in the BAL group (5.5 +/- 1.6 minutes [n = 10]), than in the ISO group (7.4 +/- 3.0 minutes [n = 16]). The addition of isoflurane (0.5-0.75% end-tidal concentration) to nitrous oxide-narcotic anesthesia augments the degree of neuromuscular blockade from a given dose of mivacurium and also prolongs the recovery index.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967644

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

3.  Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.

Authors:  W W Choi; M P Mehta; D J Murray; M D Sokoll; R B Forbes; S D Gergis; M Abou-Donia; J Kirchner
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

4.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 5.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 6.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Surgeon-controlled mivacurium administration during elective caesarean section.

Authors:  M Abdulatif; E Taylouni
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.